Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
505.10
-10.10(-2.00%)
At close: 4:00 PM EDT
505.10
-10.10(-2.00%)
Day’s Range― - ―
52-Week Range374.00 - 3,000.00
Previous CloseN/A
Volume9.36K
Average Volume (3M)1.04M
Market Cap
₪22.09M
Enterprise Value51.64
Total Cash (Recent Filing)₪8.54M
Total Debt (Recent Filing)₪71.00K
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Aug 27, 2026EPS Estimate
-48.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet FlexibilityVery low leverage reduces default and refinancing risk, giving management durable financial flexibility to fund clinical programs or pursue partnerships. With minimal debt the company can prioritize R&D and licensing without immediate debt service constraints, a structural advantage amid cash burn.
High Gross MarginsExtremely high gross margins imply favorable unit economics for the company’s small-molecule assets. If a candidate reaches commercialization, these margins would support long-term profitability and help absorb R&D and SG&A, improving sustainable cash generation and strategic optionality.
Focused Clinical-stage PipelineA concentrated pipeline focused on A3 adenosine receptor small molecules provides clear strategic optionality: successful trial readouts, approvals, or licensing of Piclidenoson/Namodenoson could materially alter revenue prospects. The focused scientific niche supports differentiated development paths and partner interest.
Bears Say
Declining RevenuePersistently tiny and shrinking revenue undermines internal funding capacity and signals limited commercial traction. Structurally weak top-line receipts increase dependence on external financing or partnerships, constrain reinvestment in trials, and limit the firm’s ability to scale operations without material changes.
Consistent Negative Cash FlowOngoing negative operating and free cash flow indicates structural cash burn to sustain development. Even with 2025 improvement, persistent negative cash generation forces dilution, debt, or strategic deals to fund programs, increasing medium-term execution and financing risk and constraining autonomy.
Large And Worsening LossesDeep and growing operating/net losses produce sharply negative returns and equity volatility. Persistent losses weaken reinvestment capacity, raise the probability of future financing needs, and limit the company's ability to pursue opportunistic growth or absorb trial setbacks without external capital or partnerships.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 374.00 and its highest was 3000.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪22.09M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 13 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -884.444 earnings per share for the quarter, missing the consensus estimate of -20.741 by -863.704.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -48.89.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -884.444 in its last earnings report, missing expectations of -20.741. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.